Targeting specific mutations in lung cancer for better treatment options
Official title: Synthetic lethal targeting of KRAS/KEAP1 co-mutant non-small cell lung cancer
Funded at Rush University Medical Center · NIH-10989208 · Data updated 2026-11-12
This study is looking at a new treatment for people with non-small cell lung cancer that has specific mutations, using a combination of two drugs, LMK235 and AMG510, to help make the treatment more effective and hopefully improve outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rush University Medical Center NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | July 3, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $340,215 |
| NIH project number | 1R01CA285743-01A1 |
| Project ID | NIH-10989208 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer that has both KRAS and KEAP1 mutations.
✕Less likely to help
Patients with non-small cell lung cancer that do not have KRAS or KEAP1 mutations may not benefit from this research.
What this research studies
This research focuses on non-small cell lung cancer (NSCLC) that has both KRAS and KEAP1 mutations, which are often resistant to standard therapies. The study investigates the use of a drug called LMK235, which inhibits a protein known as HDAC4 that is crucial for the survival of these cancer cells. By combining LMK235 with another FDA-approved drug, AMG510, the research aims to enhance the effectiveness of treatment for patients with these specific mutations. The approach involves understanding how these drugs work together to induce cancer cell death, potentially leading to improved outcomes for patients.
Why it matters
Potential benefit: If successful, this research could provide a new effective treatment option for patients with KRAS/KEAP1 co-mutant non-small cell lung cancer.
How similar studies have gone: Previous research has shown promising results with similar drug combinations in targeting specific mutations in cancer, indicating potential for success in this approach.
Where this research is happening
-
Rush University Medical Center
Chicago, United States Active
Researchers
- Principal investigator: Maki, Carl G — Rush University Medical Center
- Study coordinator: Maki, Carl G
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.